talaporfin
Trade name: Laserphyrin
Small moleculeexperimental
Talaporfin is a chlorin based photosensitizer used in photodynamic therapy (PDT). — Wikipedia
Clinical trial activity
13 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2001 (NCT00028405)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 3
- Choroidal Neovascularization · Phase 1
- Colorectal Neoplasms · Phase 3
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Head and Neck Neoplasms · Phase 1
- Liver Neoplasms · Phase 3
- Lower Urinary Tract Symptoms · Phase 2
- Macular Degeneration · Phase 1
- Mouth Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 3
- Neoplasm Recurrence, Local · Phase 3
- Neurofibroma · Phase 1
- Pelvic Neoplasms · Phase 1
- Port-Wine Stain · Phase 1
- Prostatic Hyperplasia · Phase 2
- Rectal Neoplasms · Phase 1
- Sarcoma · Phase 1
Mechanism of action
- Unspecified targetOTHER
Photosensitizing agent
Photosensitizing agent. Talaporfin sodium-mediated PDT has an antiproliferative effect, potentially through low-density lipoprotein (LDL) receptor-mediated uptake into cancer cells (PMID: 30867758) and subsequent cell damage upon light activation.
Chemistry & pharmacology
Loading structure…
SMILES
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C- Mol. weight
- 711.77 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111186 ↗
- WikipediaTalaporfin ↗
- ChEMBLCHEMBL2107806 ↗
Also known as
- laserphyrin
- laserphyrin
- l-aspartic acid, n-(3-(18-carboxy-20-(carboxymethyl)-8- ethenyl-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21h,23h- porphin-2-yl)-1-oxopropyl)-, (2s-trans)-
- ls-11
- ls-11
- me2906
- me2906
- me2906
- me2906
- monoaspartyl chlorin e6
- mono-l-aspartyl chlorin e6
- mr901
- n-aspartyl chlorin e6
- n-aspartyl chlorin e6
- n-aspartylchlorin e6
- npe6
- npe6
- talaporfin
- talaporfin
- talaporfin
- talaporfin
- talaporfin
- talaporfin
- talaporfin
- talaporfin sodium
- talaporfin sodium
- talaporfin sodium
- talaporfin sodium
- taporfin
- taporfin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02326454 | Phase 2 | Nov 1, 2014 | Light Sciences Oncology, Mundipharma |
| NCT01924273 | Phase 1 | Jun 1, 2013 | University of California, Irvine |
| NCT00918034 | Phase 2 | May 1, 2009 | Light Sciences Oncology |
| NCT00716469 | Phase 1 | Jul 1, 2008 | Department of Defense, University of Pennsylvania |
| NCT00709488 | Phase 1 | Jun 1, 2008 | Light Sciences Oncology |
| NCT00440310 | Phase 3 | Feb 1, 2007 | Light Sciences Oncology |
| NCT00409214 | Phase 2 | Nov 1, 2006 | Light Sciences Oncology |
| NCT00355355 | Phase 3 | Jul 1, 2006 | Light Sciences Oncology |
| NCT00122876 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2005 | Light Sciences Oncology |
| NCT00102115 | Phase 1 | Dec 1, 2004 | Light Sciences Oncology |
| NCT00083785 | Phase 2 | May 1, 2004 | Light Sciences Oncology |
| NCT00068068 | Phase 2 | Oct 1, 2003 | Light Sciences Oncology |
| NCT00028405 | Phase 1 | Nov 1, 2001 | Light Sciences Oncology |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Light Sciences Oncology | For profit | 11 | 11 | 3 | 2001 |
| Department of Defense | Government | 1 | 0 | 1 | 2008 |
| Mundipharma | For profit | 1 | 0 | 1 | 2014 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2008 |
5 organizations
Page 1 / 1